Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study

Hsin-Hua Chen1,2,3,4,5,6*, Wen-Cheng Chao1,7,8, Yi-Hsing Chen2,3, Tsu-Yi Hsieh2,3,9,10, Kuo-Lung Lai2,11, Yi-Ming Chen1,2,3,4,5, Wei-Ting Hung2,8, Ching-Tsai Lin2, Chih-Wei Tseng2 and Ching-Heng Lin1,12*

Abstract

Objective: To investigate the risk of immune-mediated inflammatory diseases (IMIDs) in patients with ankylosing spondylitis (AS).

Methods: Using 2003–2012 claims data from the Taiwanese National Health Insurance Research Database, we identified 30,911 newly diagnosed AS patients requiring medical therapy from 2006 to 2012. In addition, we randomly selected 309,110 non-AS individuals matching (1:10) the AS patients with regard to age, sex and the year of the index date. After excluding subjects with the corresponding prior IMIDs, we calculated the incidence rates (IRs) of various IMIDs in the AS and non-AS cohorts and estimated the hazard ratios (HRs) with 95% confidence intervals after adjusting for age, sex, the Charlson comorbidity index, the frequency of ambulatory visits during the follow-up period and medications. We conducted sensitivity analyses by excluding those who developed IMIDs within 3 months after the index date.

Results: In the follow-up period, we found that newly diagnosed AS patients had significantly increased risks of acute anterior uveitis, psoriasis, Sjögren’s syndrome, thromboangiitis obliterans, Behcet’s disease and sarcoidosis. However, the risk of Sjögren’s syndrome did not increase in AS patients in the sensitivity analysis. In the same period, this study found no significant differences in the risks of Crohn’s disease, ulcerative colitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, polymyositis, pemphigus and vitiligo between newly diagnosed AS patients and non-AS individuals. AS patients had a significantly reduced risk of rheumatoid arthritis.

Conclusion: Newly diagnosed Taiwanese AS patients had increased risks of acute anterior uveitis, psoriasis, thromboangiitis obliterans, Behcet’s disease and sarcoidosis, but a reduced risk of rheumatoid arthritis.

Keywords: Ankylosing spondylitis, Immune-mediated inflammatory disease, Incidence

Background

Immune-mediated inflammatory disease (IMID) is a term that covers a group of disorders characterised by altered immune regulation causing chronic inflammation in targeted organs or systems. IMIDs affect around 3 to 7% of the population with an estimated incidence of 80 per 10⁵ person-years [1–3]. Accumulating data from genome-wide association studies have revealed a genetic overlap among IMIDs [4]. Previous studies have shown that a patient with IMID has an increased risk of developing another IMID [5–7]. Ankylosing spondylitis (AS) is an IMID that mainly affects the axial skeleton and sometimes affects the peripheral joints and anthesis region [8], with a prevalence of 0.11 to 0.38% in Taiwan [9, 10]. In recent years, AS has been considered as a prototype of spondyloarthritis (SpA) that has been found to be associated with other IMIDs with shared immunopathogenesis referred to as extra-articular manifestations. Among the SpA concept-related extra-
articular manifestations, acute anterior uveitis (AAU), psoriasis and inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are most strongly associated with AS [11]. Several previous epidemiological studies reported the incidence and prevalence of extra-articular manifestations among AS patients [12, 13]. However, to our knowledge, no prior study had concurrently assessed the risks of developing various IMIDs in addition to SpA concept-related IMIDs (i.e. AAU, psoriasis, CD and UC) among AS patients.

The Taiwanese National Health Insurance Research Database (NHIRD) has been used to conduct population-based epidemiologic studies. The present study aimed to investigate the incidences of various IMIDs, including SpA concept-related EAMs (i.e. AAU, psoriasis, CD and UC), systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS), rheumatoid arthritis (RA), systemic sclerosis (SSc), polymyositis (PM), dermatomyositis (DMtis), thromboangiitis obliterans (TAO), Behcet’s disease (BD), sarcoidosis, pemphigus and vitiligo in a Taiwanese nationwide AS cohort compared with a matched non-AS cohort, using the NHIRD.

Methods
Study design
This was a retrospective matched cohort study.

Data source
The study data were the 2003–2012 claims data from the NHIRD. In 1995, Taiwan initiated a compulsory National Health Insurance program that currently covers over 99% of the Taiwanese population. The data of the NHIRD includes comprehensive claims data regarding medication prescription, ambulatory care services, admission services and traditional medical services. Some personal data and history data, such as body weight, body length, alcohol use and smoking, are not available in the NHIRD. The Bureau of National Health Insurance has improved the accuracy of the claims data in the NHIRD by checking original medical records regularly [14]. The National Health Research Institute manages the NHIRD and provides the database to researchers for research purpose after anonymisation of personal information.

We utilised multiple NHIRD datasets in this study, including 2003–2012 outpatient and inpatient claims data and enrollment data. We selected all newly diagnosed AS patients from 2006 to 2012 as the study cohort. The National Health Research Institute randomly selected one million individuals who were enrolled in 2000 to build a representative longitudinal health insurance database. We selected the comparison cohort from the representative population in this longitudinal database, from which we extracted 2003–2012 claims data for analysis.

For patients with severe or major diseases, such as malignancy, SLE, SSc, RA, PM, DMtis, TAO, BD, pemphigus, SS, CD and UC, the Bureau of National Health Insurance established a registry of catastrophic illness patients. Those who had a catastrophic illness certificate were exempt from copayment for all services with a corresponding catastrophic illness diagnosis. However, a catastrophic illness certificate was only issued after validation by at least two qualified specialists through a comprehensive review of the original medical charts.

Definition of AS
AS patients were considered as those having at least three ambulatory visits with a diagnosis of AS (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 720.0) and a concurrent prescription of nonsteroidal anti-inflammatory drugs (NSAIDs), sulfasalazine (SSZ), methotrexate (MTX) or corticosteroids from 2003 to 2012. In Taiwan, AS was diagnosed according to the modified New York criteria for AS proposed in 1984 [15].

Study subjects
The flow chart of study subject enrollment is shown in Fig. 1.

AS patients newly diagnosed in 2006–2012 from the entire Taiwanese population
This study included all newly diagnosed AS patients from 2006 to 2012. We excluded patients who had one or more inpatient or outpatient visits with a diagnosis of AS before 2006. We defined the index date for AS patients as the first date of outpatient or inpatient visit with a diagnosis of AS.

Matched non-AS comparison group selected from the one million nationally representative individuals in Taiwan
Non-AS individuals were considered as those having no ambulatory or inpatient diagnosis of ICD-9-CM 720.x from 2003 to 2012. We randomly selected non-AS individuals matching (1:10) the AS patients for age, sex and the year of the index date (index year) from the one million representative population in Taiwan. The time of the first ambulatory visit in the index year for any reason was used as the index date for the non-AS group.

Outcome
The outcome was the time from the index date to the time of the first outpatient or inpatient visit with the diagnosis of various IMIDs. If the IMIDs were included in the catastrophic illnesses, patients who developed these IMIDs were considered to be those who had a catastrophic illness certificate for the corresponding ICD-9-CM diagnosis.
 Patients were considered to have sarcoidosis if they had at least three outpatient visits or one inpatient visit with the corresponding ICD-9-CM diagnosis (sarcoidosis, 135). Patients were considered to have AAU if they had at least three outpatient visits or one inpatient visit involving ophthalmologists with the ICD-9-CM diagnosis code 364.00–364.02, 364.04–364.05 or 364.3. Patients were considered to have psoriasis or vitiligo if they had at least three outpatient visits or one inpatient visit involving dermatologists with the corresponding ICD-9-CM diagnosis (psoriasis, 696.1; vitiligo, 709.01). We considered the censored date as 31 December 2012 (the last date of the data used in this study) or the time of withdrawal from the National Health Insurance for various reasons, such as leaving and death, whichever came first. The follow-up duration was from the index date to the date of IMID occurrence or from the index date to the censor date. We calculated the incidences of various IMIDs by dividing the number of incident IMID cases by the sum of the follow-up durations among those who had no outpatient or inpatient visit with the corresponding IMID diagnosis before the index date.

Sensitivity analysis

To reduce the possibility that various IMIDs occurred concurrently with or earlier than AS, only patients who developed IMIDs more than 3 months after the index date were considered the incident IMID patients. We selected 3 months as the cut-off time for sensitivity analysis, given that patients usually could only arrange an outpatient appointment within 3 months in Taiwan. Therefore, if a patient suffered from various IMID-related symptoms, the diagnoses of the IMIDs may be delayed for up to 3 months.

Potential confounders

The associations between AS and the risks of various IMIDs were adjusted for potential confounders, including sex, age at the index date, comorbidity within 1 year before the index date, the frequency of ambulatory visits for any reason and concurrent medication use. We considered the matching variables (i.e. age and sex) as covariates in the multivariable Cox regression analyses because we also adjusted for additional confounders in the study [16]. We considered concomitant medications as potential confounders because they may influence the risk of IMID through immunomodulatory effects. Concurrent medications included NSAIDs, corticosteroids, MTX, SSZ, leflunomide, hydroxychloroquine and immunosuppressants (i.e. cyclosporine, azathioprine, cyclophosphamide, mycophenolate or mycophenolic acid). Because multisystem involvement of IMIDs is not uncommon, patients who had comorbidities might have an increased chance to receive investigations for IMIDs, leading to detection bias. Therefore, we also considered comorbidities as potential confounders. We used the Charlson comorbidity index (CCI) (i.e. 0, ≥1) adapted by Deyo et al. [17] to indicate the general comorbid conditions. The presence of diseases for calculating the CCI was considered as having at least three outpatient visits or at least one hospitalisation with the corresponding ICD-9-CM diagnosis within 1 year before the index date. We also considered the frequency of ambulatory visits for any reason as potential confounder given that a higher frequent visit number may introduce a greater
chance to survey another disease, leading to detection bias.

Statistical analysis
Continuous variables are presented as a mean ± standard deviation, and categorical variables are presented as the percentage of patients. We examined differences in continuous variables using Student’s t test and differences in categorical variables using Pearson’s χ² test. We quantified the associations between AS and the risks of various IMIDs by estimating hazard ratios (HRs) with 95% confidence intervals (CIs) using multivariable Cox proportional regression analysis after adjusting for potential confounders. We used six models based on the number of covariates (i.e. no adjustment; age; age and sex; age, sex and medications; age, sex, medications and the frequency of ambulatory visits; age, sex, medications, the frequency of ambulatory visits and CCI) to estimate HRs with 95% CI for the risks of IMIDs. We calculated the Akaike information criterion (AIC) for each model and selected the final models with the best model fit according to AIC (i.e. the least AIC) [18]. If two or more models had the same AIC, we selected the model with the greatest number of covariates. All statistical analyses by SAS statistical software, version 9.3 (SAS Institute, Inc., Cary, NC, USA). We considered a two-tailed P value < 0.05 as statistically significant.

Results
Baseline characteristics
The study included 30,911 newly diagnosed AS patients in the AS group and 309,110 non-AS individuals matching (1:10) the AS patients with regard to age, sex and the year of the first AS diagnosis date (index date) in the comparison group. The baseline characteristics of both groups are presented in Table 1. In both groups, the mean (± SD) age was 42 ± 17 years and 62.9% of the patients were male. The proportion of patients with a CCI of ≥ 1 was higher in the AS group than in the non-AS group. Additionally, the proportions of patients with histories of uveitis, psoriasis, UC, SLE, SS, RA, SSc, DMtis, TAO, BD, sarcoidosis and vitiligo were higher in the AS group than in the non-AS group. However, the proportions of patients with histories of CD, PM and pemphigus were not different between the AS and non-AS groups.

Incidence rates and incidence rate ratios of various IMIDs
Table 2 shows the incidence rates of IMIDs in both groups and the incidence rate ratios (IRRs) with 95% CIs in the AS group compared with the non-AS group. Among AS patients, the three highest incidence rates were identified for AAU, RA and psoriasis. On comparing AS patients and non-AS individuals, we found that AS patients had significantly higher incidence rates of BD, RA, AAU, TAO, SS, PM, SSc, UC, sarcoidosis, CD, SLE, DMtis, psoriasis and vitiligo, but not pemphigus.

Multivariable Cox regression analyses for the associations between AS and the development of IMIDs after the index date
Crude and multivariable Cox regression analyses for the relative risks of various IMIDs occurring after the index date in AS patients when compared with non-AS individuals are shown in Additional file 1: Table S1. We reveal the HRs with 95% CIs in the models with the least AIC in Table 3. The risks of developing AAU, psoriasis, CD, SS, TAO, BD and sarcoidosis were increased in AS patients. On the other hand, the risk of developing RA was lower in AS patients than in non-AS individuals. However, the risks of developing SLE, PM, DMtis, SSc,
| Autoimmune disease                  | Total   | Event (%) | Total person-years | Incidence rate (/10^5 years) | IRR (95% CI)  |
|-------------------------------------|---------|-----------|--------------------|-----------------------------|---------------|
| Acute anterior uveitis              |         |           |                    |                             |               |
| Non-AS                              | 307,265 | 420 (0.14)| 1,233,168          | 34.1                        | Reference     |
| AS                                  | 28,335  | 643 (2.13)| 103,487            | 583.6                       | 17.14 (15.13–19.41) |
| Psoriasis                           |         |           |                    |                             |               |
| Non-AS                              | 307,048 | 508 (0.17)| 1,231,732          | 41.2                        | Reference     |
| AS                                  | 30,240  | 176 (0.58)| 111,703            | 157.6                       | 3.82 (3.22–4.53) |
| Inflammatory bowel disease          |         |           |                    |                             |               |
| Non-AS                              | 299,243 | 12 (0.004)| 1,205,603          | 1.0                         | Reference     |
| AS                                  | 29,462  | 9 (0.03)  | 109,791            | 8.2                         | 8.24 (3.47–19.55) |
| Crohn's disease                     |         |           |                    |                             |               |
| Non-AS                              | 299,776 | 4 (0.001) | 1,207,612          | 0.3                         | Reference     |
| AS                                  | 29,560  | 3 (0.01)  | 110,132            | 2.7                         | 8.22 (1.84–36.75) |
| Ulcerative colitis                  |         |           |                    |                             |               |
| Non-AS                              | 308,500 | 8 (0.003) | 1,238,652          | 0.6                         | Reference     |
| AS                                  | 30,793  | 7 (0.02)  | 114,074            | 6.1                         | 9.50 (3.45–26.20) |
| Systemic lupus erythematosus        |         |           |                    |                             |               |
| Non-AS                              | 308,500 | 40 (0.01) | 1,238,580          | 3.2                         | Reference     |
| AS                                  | 30,517  | 29 (0.10) | 113,090            | 25.6                        | 88.20 (11.03–705.18) |
| Sjögren's syndrome                  |         |           |                    |                             |               |
| Non-AS                              | 306,049 | 80 (0.03) | 1,230,358          | 6.5                         | Reference     |
| AS                                  | 29,772  | 91 (0.31) | 110,650            | 82.2                        | 12.65 (9.37–17.08) |
| Rheumatoid arthritis                |         |           |                    |                             |               |
| Non-AS                              | 305,326 | 112 (0.04)| 1,226,848          | 9.1                         | Reference     |
| AS                                  | 27,531  | 190 (0.69)| 102,233            | 185.9                       | 20.36 (16.12–25.71) |
| Systemic sclerosis                  |         |           |                    |                             |               |
| Non-AS                              | 309,048 | 9 (0.003) | 1,240,674          | 0.7                         | Reference     |
| AS                                  | 30,872  | 8 (0.03)  | 114,346            | 7.0                         | 9.64 (3.72–25.00) |
| Dermatomyositis                     |         |           |                    |                             |               |
| Non-AS                              | 308,846 | 8 (0.003) | 1,239,911          | 0.6                         | Reference     |
| AS                                  | 30,843  | 4 (0.01)  | 114,233            | 3.5                         | 5.43 (1.63–18.02) |
| Polymyositis                        |         |           |                    |                             |               |
| Non-AS                              | 308,832 | 2 (0.001) | 1,239,818          | 0.2                         | Reference     |
| AS                                  | 30,827  | 2 (0.001) | 114,166            | 1.8                         | 10.86 (1.53–77.10) |
| Thromboangiitis obliterans          |         |           |                    |                             |               |
| Non-AS                              | 309,093 | 2 (0.001) | 1,240,854          | 0.2                         | Reference     |
| AS                                  | 30,907  | 3 (0.01)  | 114,474            | 2.6                         | 16.26 (2.72–97.31) |
| Behcet's disease                    |         |           |                    |                             |               |
| Non-AS                              | 309,039 | 4 (0.001) | 1,240,654          | 0.3                         | Reference     |
| AS                                  | 30,820  | 21 (0.07) | 114,144            | 18.4                        | 57.06 (19.59–166.24) |
| Pemphigus                           |         |           |                    |                             |               |
| Non-AS                              | 309,061 | 4 (0.001) | 1,240,728          | 0.3                         | Reference     |
| AS                                  | 30,906  | 2 (0.01)  | 114,477            | 1.7                         | 5.42 (0.99–29.59) |
| Sarcoidosis                         |         |           |                    |                             |               |
pemphigus, UC and vitiligo did not differ significantly between AS patients and non-AS individuals.

Sensitivity analysis for the risks of IMIDs excluding those with IMID within 3 months after the index date in AS patients

Crude and multivariable Cox regression analyses for the relative risks of various IMIDs excluding those with IMID within 3 months after the index date in AS patients when compared with non-AS individuals are shown in Additional file 2: Table S2. We reveal the HRs with 95% CIs in the models with the least AIC in Table 3. The risks of AAU, psoriasis, TAO, BD and sarcoidosis remained significantly higher in AS patients than in non-AS individuals. On the other hand, the risk of RA was significantly lower in AS patients compared with controls. However, the risks of SLE, PM, DMtis, SSc, pemphigus, SS, CD, UC and vitiligo were not significantly different between AS patients and non-AS individuals.

Discussion

To our knowledge, our study is the first to concurrently estimate the relative risks of developing various IMIDs in addition to SpA concept-related IMIDs (i.e. AAU, psoriasis, CD and UC) in AS patients when compared with non-AS individuals. Considering the data of model fitting and sensitivity analyses, we found that newly diagnosed AS patients had increased risks of AAU, psoriasis, TAO, BD and sarcoidosis, but a decreased risk of RA. Consistent with the findings in previous studies [12, 19], the risks of developing SpA concept-related comorbidities, including uveitis and

Table 2 Comparison of the incidence rates of developing various immune-mediated inflammatory diseases between AS patients and non-AS individuals (Continued)

| Autoimmune disease | Total Event (%) | Total person-years | Incidence rate (/10^5 years) | IRR (95% CI) |
|--------------------|----------------|--------------------|-----------------------------|--------------|
| Non-AS 309,088     | 21 (0.01)      | 1,240,775          | 1.7                         | Reference    |
| AS 30,897          | 16 (0.05)      | 114,402            | 14.0                        | 8.26 (4.31–15.84) |

Vitiligo

| Total Event (%) | Total person-years | Incidence rate (/10^5 years) | IRR (95% CI) |
|-----------------|--------------------|-----------------------------|--------------|
| Non-AS 308,750  | 98 (0.03)          | 1,239,523                   | 7.9          | Reference    |
| AS 30,838       | 21 (0.07)          | 114,251                     | 18.4         | 2.32 (1.45–3.72) |

Abbreviations: AS ankylosing spondylitis, IRR incidence rate ratio, CI confidence interval

Table 3 Multivariable Cox regression analyses for the relative risks of developing various IMIDs in AS patients when compared with non-AS individuals

| IMID | IMID occurred after the index date | Excluding those with IMID within 3 months after the index date |
|------|-----------------------------------|---------------------------------------------------------------|
| Acute anterior uveitis | 9.07 (7.52–10.94) | 10.98 (9.10–13.25) |
| Psoriasis | 1.69 (1.24–2.29) | 1.41 (1.01–1.96) |
| Inflammatory bowel disease | 2.11 (0.39–11.48) | 0.35 (0.06–2.06) |
| Crohn’s disease | 8.01 (1.79–35.79) | 2.74 (0.31–24.52) |
| Ulcerative colitis | 0.33 (0.05–2.37) | 0.33 (0.05–2.37) |
| Systemic lupus erythematosus | 0.93 (0.49–1.79) | 0.81 (0.40–1.64) |
| Sjögren’s syndrome | 2.05 (1.39–3.01) | 1.29 (0.84–1.99) |
| Rheumatoid arthritis | 0.70 (0.50–0.99) | 0.46 (0.33–0.65) |
| Systemic sclerosis | 1.65 (0.45–6.02) | 1.65 (0.45–6.02) |
| Dermatomyositis | 0.95 (0.22–4.02) | 0.29 (0.04–1.99) |
| Polymyositis | 7.96 (0.97–65.56) | 7.96 (0.97–65.56) |
| Thromboangiitis obliterans | 16.62 (2.78–99.52) | 16.62 (2.78–99.52) |
| Behçet’s disease | 20.37 (5.54–74.85) | 26.20 (6.27–109.45) |
| Pemphigus | 0.97 (0.07–13.48) | 0.97 (0.07–13.48) |
| Sarcoidosis | 5.39 (2.15–13.48) | 6.09 (2.38–15.58) |
| Vitiligo | 1.55 (0.73–3.32) | 1.42 (0.63–3.22) |

Abbreviations: AS ankylosing spondylitis, IMID immune-mediated inflammatory disease, HR hazard ratio, CI confidence interval

Adjusted variables: *none; +age; +age and sex; +age, sex and medications; +age, sex, medications and the frequency of visits; +age, sex, medications, the frequency of visits and Charlson comorbidity index. Models with the least Akaike information criterion were selected.
Psoriasis, were higher in newly diagnosed AS patients compared with non-AS individuals. However, inconsistent with the findings in previous studies [12, 19, 20], we failed to demonstrate statistically significant differences in the risks of UC and CD between newly diagnosed AS patients and non-AS individuals after adjusting potential confounders. Because IBD was increased at baseline, it is likely that the failure to identify a clinical association of AS with IBD was because the onset of IBD in most cases was prior to the baseline for study entry. Other possible explanations of this inconsistency included the adjustment of many covariates, possible AS diagnosis delay and the low incidences of CD and UC in Taiwan [21].

After adjusting for potential confounders, we found a positive correlation between AS and the development of SS. However, the risk of developing SS did not significantly increase in newly diagnosed AS patients after excluding patients who developed SS within 3 months after the index date. The inconsistent finding in the sensitivity analysis might be explained by the presence of radiographic sacroiliitis in a significant proportion (24.7%) of primary SS patients reported by Eren et al. [22] and the insidious onset of SS [23].

We also found that newly diagnosed AS patients had an increased risk of developing TAO and BD. In 1999, Puéchal et al. found that 11 (12.5%) of 83 patients with TAO had initial rheumatic manifestations. Of them, two patients had HLA-B27-positive SpA and one presented with oligoarthritis [24]. In 2015, Lpoalco et al. also reported the coexistence of axial SpA and TAO in a young woman [25]. Possible explanations for the linkage of AS with TAO include shared genetic risk factors, e.g. HLA-B40 [26, 27], and environmental risk factors, e.g. smoking [28, 29]. In 1974, Moll et al. revealed associations among AS, psoriatic arthritis, Reiter’s syndrome, intestinal arthropathies and BD and suggested that SpA complex could include BD [30]. Many cases with the coexistence of AS and BD have also been reported [31–42]. A prior study investigating the skeletal manifestations in 79 BD patients found that 5% of them had definite AS [43]. There are some possible explanations for the markedly increased risk of BD in newly diagnosed AS patients. First, AS and BD had shared genetic associations with MHC class I, interleukin 23 receptor (IL23R) and endoplasmic reticulum aminopeptidase 1 (ERAP1) [44]. Second, similar inflammatory cytokine profiles in synovial fluid existed in AS and BD patients [45], indicating the similarities in the pathogeneses of AS and BD. Third, a previous study showed that articular symptoms, including spinal pain, were the first disease manifestation in 16.5% of 79 BD patients [43]. Therefore, some BD patients might be misdiagnosed as AS initially.

The present study showed that newly diagnosed AS patients had an increased risk of sarcoidosis. Wu et al. found that sarcoidosis patients had an increased risk of comorbid AS (adjusted odds ratio, 3.80; 95% CI, 2.42–5.97) [46]. We also found that the proportion of patients with a history of sarcoidosis was higher among AS patients than among non-AS individuals. Kim et al. found that sarcoidosis was associated with the IL23R gene [47], and it is known that AS is also associated with this gene. Of note, several case reports indicated an association between tumour necrosis inhibitors, which are used for AS therapy, and the development of sarcoidosis [48, 49]. We found a negative association between AS and the risk of RA development. This negative association may be explained by the distinct major genetic risk loci between AS (MCH class I/IL23R/ERAP1) and RA (MHC class II/PTPN22/STAT4/IRF5) [44].

The strengths of this study are the minimisation of selection bias and the inclusion of adequate incident cases with IMIDs using a nationwide population-based database. However, this study has some limitations. First, the accuracy of the diagnosis of AS according to claims data is concerning. Therefore, false positive and false negative diagnoses may occur both in the AS group and the comparison group. However, the accuracy of the diagnosis has improved following a routine inspection of the original medical records [14]. Second, the ICD-9-CM code for pemphigus (i.e. 694.4) includes different entities like pemphigus vulgaris, pemphigus foliaceous and others. Although these disease entities shared the feature of immune-mediated acantholysis, such diagnostic pooling was still of concern. Third, although we used several methods to improve the accuracy of IMID diagnoses, the detection rates of IMIDs in AS patients may not be equal to those in non-AS individuals. However, we minimised such differential detection bias by adjusting the frequency of ambulatory visits to decrease the possibility of an overestimation of the risks of IMIDs in AS patients. Fourth, some potential confounding factors, including socioeconomic status, smoking history, drinking history and family history, were not recorded in the NHIRD. Fifth, by focusing on incidence, the study design loses power to identify clinical association between AS and IBD. Finally, it might not be possible to extrapolate the study results, especially the IBD results, to non-Taiwanese populations.

Conclusions
This nationwide, population-based, cohort study showed newly diagnosed AS patients had increased risks of AAU, psoriasis, TAO, BD and sarcoidosis and a decreased risk of RA. These significant associations indicate potential shared or distinct genetic, pathogenic and clinical relationships between AS and these IMIDs and also suggest that physicians should survey symptoms and signs related to the positively correlated IMIDs when managing AS patients. Further
clinical, genetic and pathogenic studies are also necessary to elucidate the role of AS in the development of uveitis, psoriasis, TAO, BD and sarcoidosis and to identify the risk factors or predictors.

Additional files

| File | Description | Files size |
|------|-------------|------------|
| Additional file 1: Table S1 | Crude and multivariable Cox regression analyses for the relative risks of various IMIDs occurring after the index date in AS patients when compared with non-AS individuals. (DOCX 23 kb) |
| Additional file 2: Table S2 | Crude and multivariable Cox regression analyses for the relative risks of developing various IMIDs excluding those with IMD within three months after the index date in AS patients when compared with non-AS individuals. (DOCX 24 kb) |

Abbreviations

AS: Ankylosing spondylitis; BD: Behcet’s disease; CCI: Charlson comorbidity index; CD: Crohn’s disease; CI: Confidence interval; DMIs: Dermatomyositis; ERAPI: Endoplasmic reticulum aminopeptidase 1; HR: Hazard ratio; IBD: Inflammatory bowel disease; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification; IL23R: Interleukin 23 receptor; IMID: Immune-mediated inflammatory disease; IRR: Incidence rate ratio; MTX: Methotrexate; NHIRD: National Health Insurance Research Database; NSAID: Nonsteroidal anti-inflammatory drugs; RA: Rheumatoid arthritis; SpA: Spondyloarthritis; SLE: Systemic lupus erythematosus; SS: Sjögren’s syndrome; SSC: Systemic sclerosis; SD: Standard deviation; SSZ: Sulfasalazine; TAO: Thromboangiitis obliterans; UC: Ulcerative colitis

Acknowledgements

The study is based on data from the National Health Insurance Research Database provided by the National Health Insurance Administration and the Ministry of Health and Welfare or the National Health Insurance Research Institute. The interpretation and conclusions do not represent those of the National Health Insurance Administration, the Ministry of Health and Welfare or the National Health Research Institutes. The authors would like to thank the Biostatistics Task Force of Taichung Veterans General Hospital, Taichung, Taiwan, ROC for statistical support.

Ethics approval and consent to the participate state

The Institutional Review Board of Taichung Veterans General Hospital, Taichung, Taiwan. The requirement for informed consent was waived as personal information was anonymised before data analyses.

Authors’ contributions

HHC contributed to the conception, design and the first draft of writing of the work. WCC contributed to the design of the work, interpretation of the data and revision of the initial writing. YHC contributed to the conception, design of the work and interpretation of the data. TYH, KLI, YMC and WTH contributed to the conception of the work and interpretation of the data. CHL contributed to the acquisition and analysis of data, software for analysis and validation of the final manuscript. All authors read and approved the final manuscript.

Funding

This study did not receive any funding support.

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan. 2Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. 3School of Medicine, National Yang-Ming University, Taipei, Taiwan. 4Institute of Biomedical Science and Rong-Hsing Research Center for Translational Medicine, Chung-Hsing University, Taichung, Taiwan. 5Institute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan. 6Department of Industrial Engineering and Enterprise Information, Tunghai University, Taichung, Taiwan. 7Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. 8Department of Nursing, College of Medicine & Nursing, Hung Kuang University, Taichung, Taiwan. 9Department of Medical Education, Taichung Veterans General Hospital, Taichung, Taiwan. 10Ph.D. Program of Business, Feng Chia University, Taichung, Taiwan. 11Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan. 12Department of Healthcare Management, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.

Received: 29 March 2019 Accepted: 16 August 2019

Published online: 29 August 2019

References

1. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119–25.
2. El-Gabalawy H, Guenther LC, Bernstein CN. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl. 2010;85(2):10–9.
3. Kuek A, Hazeland BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(788):251–60.
4. David T, Ling SF, Barton A. Genetics of immune-mediated inflammatory diseases. Clin Exp Immunol. 2018;193:3–12.
5. Robinson D Jr, Hackett M, Wong J, Kimball AB, Cohen R, Bala M, Group IS. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001–2002. Curr Med Res Opin. 2006;22(5):989–1000.
6. Cohen R, Robinson D Jr, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001–2002. Inflamm Bowel Dis. 2008;14(6):738–43.
7. Brophy S, Pavy S, Lewis P, Taylor G, Bradbury L, Robertson D, Lovell C, Cain A. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol. 2001;28(12):2667–73.
8. Sieper J, Podobnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84.
9. Chou CT, Pei L, Chang DM, Lee CF, Schumacher HR, Liang MH. Prevalence of rheumatic diseases in Taiwan: a population study of urban, suburban, rural differences. J Rheumatol. 1994;21(2):302–6.
10. Chen HH, Chen TJ, Chen YM, Ying-Ming C, Chen DY. Gender differences in ankylosing spondylitis-associated cumulative healthcare utilization: a population-based cohort study. Clinics. 2011;66(2):251–4.
11. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65–73.
12. Stolwijk C, Essers I, van Tubergen A, Boonen A, Bazelier MT, De Bruin ML, de Vries F. The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis. 2015;74(7):1373–83.
13. Ho HH, Chen JY. Ankylosing spondylitis: Chinese perspective, clinical phenotypes, and associated extra-articular systemic features. Curr Rheumatol Rep. 2013;15(8):344.
14. Cheng TM. Taiwan’s new national health insurance program: genesis and experience so far. Health Aff. 2003;22(3):61–76.
15. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–8.
16. Sjölander A, Greenland S. Ignoring the matching variables in cohort studies - when is it valid and why? Stat Med. 2013;32(7):496–708.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.
18. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19(6):716–23.

19. Lee JS, Oh BL, Lee HY, Song YW, Lee EY. Comorbidity, disability, and healthcare expenditure of ankylosing spondylitis in Korea: a population-based study. PLoS One. 2018;13(2):e0192524.

20. Bae JM, Choo JY, Kim KJ, Park KS. Association of inflammatory bowel disease with ankylosing spondylitis and rheumatoid arthritis: a nationwide population-based study. Mod Rheumatol. 2017;27(3):435–40.

21. Yen HH, Weng MT, Tung CC, Wang YT, Chang YT, Chang CH, Shieh MJ, Chen YH. The prevalence of inflammatory bowel disease in patients with primary Sjögren's syndrome: a nationwide population-based study. Intest Res. 2019;17(1):54–62.

22. Eren R, Can M, Alibaz-Onel F, Yilmaz-Onel S, Yilmazer B, Cefle A, Direskeneli H, Atagunduz P. Prevalence of inflammatory back pain and radiologic sacroiliitis is increased in patients with primary Sjögren's syndrome. Pan Afr Med J. 2018;30:98.

23. Olate S, Munoz D, Neumann S, Pozzer L, Cavalieri-Pereira L, de Moraes M. A descriptive study of the oral status in subjects with Sjögren's syndrome. Int J Clin Exp Med. 2014;7(4):1140–4.

24. Puechaut X, Fieschinger JM, Kahan A, Menkes CJ. Rheumatic manifestations in patients with thrombocytopenia obliterans (Buerger's disease). J Rheumatol. 1999;26(8):1764–8.

25. Lopalco G, Iannone F, Rigante D, Vitale A, Mancini ME, Covelli M, Lapadula P. Coexisting ankylosing spondylitis and thromboangiitis obliterans in a young woman. Reumatismo. 2015;67(1):17–20.

26. Diaz-Peña R, Vidal-Castineira JR, Lopez-Larrea C. HLA-B*40:01 is associated with ankylosing spondylitis in HLA-B27-positive populations. J Rheumatol. 2016;43(6):1255–6.

27. Fernandez-Miranda C, Rubio R, Vicario JL, Arnaiz A, Fernandez Saez R, Mollejo M, Pulido F, del Palacio A, Lazaro T. Thrombocytopenia obliterans (Buerger's disease). Study of 41 cases. Med Clin. 1993;101(9):321–6.

28. Videm V, Cortes A, Thomas R, Brown MA. Current smoking is associated with incident ankylosing spondylitis — the HUNT population-based Norwegian health study. J Rheumatol. 2014;41(10):2041–8.

29. Mills JL Sr. Buerger's disease in the 21st century: diagnosis, clinical features, and therapy. Semin Vasc Surg. 2003;16(3):179–89.

30. Moll JM, Haslock I, Macrae IF, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome. Medicine (Baltimore). 1974;53(3):343–64.

31. Yoo WH. Coexisting Behcet's disease and ankylosing spondylitis. J Rheumatol. 1996;23(6):619–20.

32. Frigui M, Kechau M, Jallouli M, Zerrouki M, Chaabouni HB, Bahloul Z. Coexistence of Behcet's disease with ankylosing spondylitis and familial Mediterranean fever: a rare occurrence. Clin Pract. 2011;1(2):e34.

33. Tosun M, Uslu T, Ibrahim Inanoglu H, Bahadir S, Erdolu S, Guler M. Coexisting ankylosing spondylitis and Behcet's disease. Clin Rheumatol. 1999;15(6):619–20.

34. Laroche C, Cremer GA, Patri B, Remy JM, Letellier P. Association of Behcet's disease and pelvispondylitis in a subject without HLA W 27 antigen. Sem Hup. 1975;5(3):2501–8.

35. Olivieri I, Gemignani G, Busoni F, Pecori F, Camerini E, Trippi D, Pasero G. Ankylosing spondylitis with predominant involvement of the cervical spine in a woman with Behcet's syndrome. Ann Rheum Dis. 1988;47(9):780–3.

36. Beiran I, Scharf J, Dori D, Miller B. A change in ocular involvement in a patient suffering from ankylosing spondylitis and Behcet's disease. Eur J Ophthalmol. 1995;5(3):192–4.

37. Kallel MH, Beija J, Fournie B, Fournie A. Behcet syndrome with ankylosing spondylitis. Rev Rhum Engl Ed. 1995;62(4):295–9.

38. Borman P, Bodur H, Ak G, Bostan EE, Barca N. The coexistence of Behcet's disease and ankylosing spondylitis. Rheumatol Int. 2000;19(5):195–8.

39. Chang HK, Cho EH, Kim JU, Heer H. A case of coexisting Behcet's disease and ankylosing spondylitis. Korean J Intern Med. 2000;15(1):93–5.

40. Cimen OB, Sahin G, Bicer A, Erdogan C. Behcet's syndrome coexisting with clinically occult ankylosing spondylitis. South Med J. 2002;95(11):1355–6.

41. Tsaoou N, Benyahya E, Bennis R, Milioni O. Ankylosing spondylitis and Behcet's disease in combination. Two case reports. Joint Bone Spine. 2002;69(1):96–8.

42. Kotovgul N. Coexistence of ankylosing spondylitis and Behcet's disease. Two cases with atypical presentation and course. Scand J Rheumatol. 2003;32(3):184–5.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions